Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

cabazitaxel

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Microtubule inhibitor

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	carboplatin + cabazitaxel Sensitive: A2 - Guideline carboplatin + cabazitaxel Sensitive : A2	carboplatin + cabazitaxel Sensitive: A2 - Guideline carboplatin + cabazitaxel Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	carboplatin + cabazitaxel Sensitive: A2 - Guideline carboplatin + cabazitaxel Sensitive : A2	carboplatin + cabazitaxel Sensitive: A2 - Guideline carboplatin + cabazitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	cabazitaxel Sensitive: C2 – Inclusion Criteria cabazitaxel Sensitive : C2	cabazitaxel Sensitive: C2 – Inclusion Criteria cabazitaxel Sensitive : C2
HER-2 amplification	Gastric Cancer	HER-2 amplification	Gastric Cancer	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3
AR-V7 positive	Prostate Cancer	AR-V7 positive	Prostate Cancer	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3
AR-V7 expression	Prostate Cancer	AR-V7 expression	Prostate Cancer	cabazitaxel Resistant: C3 – Early Trials cabazitaxel Resistant : C3	cabazitaxel Resistant: C3 – Early Trials cabazitaxel Resistant : C3
TUBB1 rs151352	Prostate Cancer	TUBB1 rs151352	Prostate Cancer	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3
CYP2C8 rs1058932	Prostate Cancer	CYP2C8 rs1058932	Prostate Cancer	cabazitaxel Resistant: C3 – Early Trials cabazitaxel Resistant : C3	cabazitaxel Resistant: C3 – Early Trials cabazitaxel Resistant : C3
CYP2C8 rs1341164	Prostate Cancer	CYP2C8 rs1341164	Prostate Cancer	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3	cabazitaxel Sensitive: C3 – Early Trials cabazitaxel Sensitive : C3
BRCA2 A902fs*2	Prostate Cancer	BRCA2 A902fs*2	Prostate Cancer	docetaxel + cabazitaxel Resistant: C4 – Case Studies docetaxel + cabazitaxel Resistant : C4	docetaxel + cabazitaxel Resistant: C4 – Case Studies docetaxel + cabazitaxel Resistant : C4